Immune Checkpoint Inhibitors: a translational drug discovery case study
Focus keyword: immune checkpoint inhibitors Immune checkpoint inhibitors (ICIs) revolutionized oncology by modulating immune regulation instead of directly targeting tumor cells. ICIs block CTLA-4 and PD-1/PD-L1 pathways that restrain T-cell activation. This case study shows immunology becoming real-world therapy. Nature immuno-oncology overview. Why Immune Checkpoint Inhibitors Matter Immune checkpoint inhibitors show the complete "bench-to-bedside" arc: Hypothesis → target validation → therapeutic engineering Clinical development → post-approval refin
by